Unnamed: 0,title,date,stock,sentiment
1088824.0,"Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.",2020-06-08 11:41:00-04:00,RIGL,positive
1088825.0,"JP Morgan Maintains Overweight on Rigel Pharmaceuticals, Lowers Price Target to $6",2020-05-27 10:20:00-04:00,RIGL,negative
1088826.0,"Rigel Pharmaceuticals Q1 EPS $0.130, Inline, Sales $55.761M Miss $56.710M Estimate",2020-05-05 16:10:00-04:00,RIGL,negative
1088827.0,Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.,2020-05-05 12:44:00-04:00,RIGL,positive
1088828.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,RIGL,positive
1088829.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,RIGL,neutral
1088830.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,RIGL,positive
1088831.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,RIGL,negative
1088832.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-19 10:49:00-04:00,RIGL,negative
1088833.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,RIGL,neutral
1088834.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,RIGL,positive
1088835.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,RIGL,negative
1088836.0,"Rigel Pharmaceuticals Q4 EPS $(0.1) Misses $(0.08) Estimate, Sales $15.4M Miss $15.62M Estimate",2020-02-27 16:04:00-05:00,RIGL,negative
1088837.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,RIGL,positive
1088838.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,RIGL,neutral
1088839.0,22 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-02-20 07:56:00-05:00,RIGL,neutral
1088840.0,15 Biotechnology Stocks Moving In Thursday's After-Market Session,2020-01-23 23:28:00-05:00,RIGL,neutral
1088841.0,20 Healthcare Stocks Moving In Thursday's After-Market Session,2020-01-23 23:13:00-05:00,RIGL,neutral
1088842.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,RIGL,neutral
1088843.0,70 Biggest Movers From Yesterday,2020-01-23 05:52:00-05:00,RIGL,neutral
1088844.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,RIGL,neutral
1088845.0,116 Healthcare Stocks Moving In Wednesday's Session,2020-01-22 12:37:00-05:00,RIGL,neutral
1088846.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,RIGL,negative
1088847.0,76 Biggest Movers From Yesterday,2020-01-17 04:54:00-05:00,RIGL,neutral
1088848.0,Rigel Pharmaceuticals shares are trading higher. Not seeing any company-specific news to justify the price action.,2020-01-16 15:54:00-05:00,RIGL,positive
1088849.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,RIGL,neutral
1088850.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,RIGL,neutral
1088851.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-15 13:14:00-05:00,RIGL,neutral
1088852.0,80 Biggest Movers From Yesterday,2020-01-15 04:48:00-05:00,RIGL,neutral
1088853.0,48 Stocks Moving In Tuesday's Mid-Day Session,2020-01-14 12:06:00-05:00,RIGL,neutral
1088854.0,Rigel Pharmaceuticals shares are trading higher on above-average volume. Not seeing any news to justify the price action.,2020-01-14 11:39:00-05:00,RIGL,positive
1088855.0,"Rigel Pharmaceuticals Sees Prelim. Q4 Net Product Sales $13.8M, Total Revenues ~$15.9M",2020-01-13 07:31:00-05:00,RIGL,neutral
1088856.0,"The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data",2019-12-18 07:23:00-05:00,RIGL,positive
1088857.0,"BMO Capital Maintains Outperform on Rigel Pharmaceuticals, Lowers Price Target to $8",2019-12-09 09:48:00-05:00,RIGL,negative
1088858.0,35 Stocks Moving in Friday's Pre-Market Session,2019-11-15 07:52:00-05:00,RIGL,neutral
1088859.0,Rigel Reports Positive CHMP Opinion For Fostamatinib Disodium Hexahydrate For Adult Patients With Chronic Immune Thrombocytopenia In Europe,2019-11-15 07:34:00-05:00,RIGL,positive
1088860.0,"Cantor Fitzgerald Maintains Overweight on Rigel Pharmaceuticals, Lowers Price Target to $5",2019-11-15 07:27:00-05:00,RIGL,negative
1088861.0,"Rigel Pharmaceuticals Q3 EPS $(0.07) Beats $(0.13) Estimate, Sales $11.716M Miss $11.95M Estimate",2019-11-05 16:48:00-05:00,RIGL,negative
1088862.0,Rigel Pharmaceuticals  shares are trading higher despite no company-specific news. This could potentially be in sympathy with Immunogen after the company reported better-than-expected Q3 earnings results.,2019-11-01 13:48:00-04:00,RIGL,positive
1088863.0,46 Biggest Movers From Yesterday,2019-10-29 05:39:00-04:00,RIGL,neutral
1088864.0,Rigel Pharmaceuticals shares are trading higher. Not yet seeing any company-specific news.,2019-10-28 13:40:00-04:00,RIGL,positive
1088865.0,Rigel Pharmaceuticals shares are trading higher on seemingly no company-specific news.,2019-10-24 10:35:00-04:00,RIGL,neutral
1088866.0,Rigel Pharmaceuticals Provides Business Update Prior To Investor & Analyst Call,2019-10-23 07:34:00-04:00,RIGL,neutral
1088867.0,Stocks That Hit 52-Week Lows On Friday,2019-10-18 10:36:00-04:00,RIGL,negative
1088868.0,32 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-10-18 08:34:00-04:00,RIGL,neutral
1088869.0,Rigel Pharma Reports Positive Trend Vote From CHMP For Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia In Europe,2019-10-18 07:35:00-04:00,RIGL,positive
1088870.0,"The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe",2019-10-18 07:07:00-04:00,RIGL,neutral
1088871.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,RIGL,neutral
1088872.0,21 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-09-26 08:10:00-04:00,RIGL,neutral
1088873.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,RIGL,negative
1088874.0,Rigel's fostamatinib Enters Phase 3 Clinical Trial In Japan With Kissei Pharmaceuticals For The Treatment Of Chronic Immune Thrombocytopenia,2019-09-23 07:30:00-04:00,RIGL,positive
1088875.0,Rigel Pharmaceuticals shares are trading lower. The stock broke below the $2 support level and continued to trade lower ever since.,2019-09-12 15:31:00-04:00,RIGL,negative
1088876.0,Stocks That Hit 52-Week Lows On Wednesday,2019-09-04 11:39:00-04:00,RIGL,negative
1088877.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,RIGL,positive
1088878.0,"The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved",2019-08-28 07:31:00-04:00,RIGL,positive
1088879.0,"The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission",2019-08-16 07:33:00-04:00,RIGL,negative
1088880.0,Rigel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-08-06 17:58:00-04:00,RIGL,positive
1088881.0,"Rigel Pharmaceuticals Q2 EPS $(0.12) Beats $(0.14) Estimate, Sales $10.41M Beat $9.28M Estimate",2019-08-06 16:02:00-04:00,RIGL,neutral
1088882.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,RIGL,positive
1088883.0,Rigel Pharma Reports First Patient Enrolled In Phase 3 Trial Of Fostamatinib Disodium Hexahydrate In Warm Autoimmune Hemolytic Anemia,2019-05-16 07:32:00-04:00,RIGL,positive
1088884.0,Rigel Pharmaceuticals Opened Clinical Trial Sites For Phase 3 Study Of Fostamatinib In Warm Autoimmune Hemolytic Anemia; Expects To Enroll First Patient This Month,2019-05-07 17:35:00-04:00,RIGL,positive
1088885.0,"Rigel Pharmaceuticals Q1 EPS $(0.11) Beats $(0.13) Estimate, Sales $12.624M Beat $11.37M Estimate",2019-05-07 17:34:00-04:00,RIGL,neutral
1088886.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,RIGL,neutral
1088887.0,"Rigel Pharmaceuticals Q4 EPS $0.02 Misses $0.03 Estimate, Sales $37.86M Beat $36.35M Estimate",2019-02-28 16:48:00-05:00,RIGL,negative
1088888.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,RIGL,positive
1088889.0,Rigel Rises On European Marketing Agreement For Autoimmune Drug,2019-01-23 10:20:00-05:00,RIGL,positive
1088890.0,"Rigel Pharmaceuticals Enters Collaboration And License Agreement With Grifols, S.A. To Commercialize Fostamatinib In Europe; Co. To Receive $30M Upfront Cash Payment With $297.5M In Potential Milestones",2019-01-23 07:32:00-05:00,RIGL,positive
1088891.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,RIGL,neutral
1088892.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,RIGL,positive
1088893.0,Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved,2018-12-18 08:55:00-05:00,RIGL,positive
1088894.0,"Rigel Pharmaceuticals, Inc. Q3 EPS $(0.14) Beats $(0.15) Estimate, Sales $4.865M Beat $3.93M Estimate",2018-11-06 16:11:00-05:00,RIGL,neutral
1088895.0,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",2018-11-06 07:04:00-05:00,RIGL,positive
1088896.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,RIGL,neutral
1088897.0,Rigel Pharma Enters Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize TAVALISSE in Japan and other Asian Countries,2018-10-29 08:01:00-04:00,RIGL,positive
1088898.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-10-11 09:10:00-04:00,RIGL,neutral
1088899.0,Rigel Pharma Reports Received EMA Validation Of Marketing Authorization Application For Fostamatinib Disodium Hexahydrate In Chronic ITP In Adult Patients,2018-10-11 07:32:00-04:00,RIGL,neutral
1088900.0,56 Biggest Movers From Yesterday,2018-09-21 04:48:00-04:00,RIGL,neutral
1088901.0,40 Biggest Movers From Yesterday,2018-08-29 05:18:00-04:00,RIGL,neutral
1088902.0,30 Stocks Moving In Tuesday's Mid-Day Session,2018-08-28 12:20:00-04:00,RIGL,neutral
1088903.0,30 Stocks Moving In Tuesday's Pre-Market Session,2018-08-28 08:02:00-04:00,RIGL,neutral
1088904.0,30 Stocks Moving In Monday's Mid-Day Session,2018-08-27 12:49:00-04:00,RIGL,neutral
1088905.0,"Benzinga's Top Upgrades, Downgrades For August 27, 2018",2018-08-27 09:31:00-04:00,RIGL,positive
1088906.0,24 Stocks Moving In Monday's Pre-Market Session,2018-08-27 08:40:00-04:00,RIGL,neutral
1088907.0,"Citigroup Initiates Coverage On Rigel Pharmaceuticals with Buy Rating, Announces $8.50 Price Target",2018-08-27 07:48:00-04:00,RIGL,neutral
1088908.0,77 Biggest Movers From Yesterday,2018-08-10 04:01:00-04:00,RIGL,neutral
1088909.0,68 Stocks Moving In Thursday's Mid-Day Session,2018-08-09 12:41:00-04:00,RIGL,neutral
1088910.0,Rigel Pharmaceuticals shares are trading 14.6% higher after announcing quarterly financial results anchored by strong sales figures.,2018-08-09 11:46:00-04:00,RIGL,positive
1088911.0,"The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings",2018-08-09 08:39:00-04:00,RIGL,positive
1088912.0,40 Stocks Moving In Thursday's Pre-Market Session,2018-08-09 08:09:00-04:00,RIGL,neutral
1088913.0,Rigel Pharma shares up 8.6% after hours following a Q2 loss which was inline with analysts' consensus estimate but very strong sales figures.,2018-08-08 18:12:00-04:00,RIGL,positive
1088914.0,"Rigel Pharmaceuticals Q2 EPS $(0.16), Inline, Sales $1.787M Beat $180K Estimate",2018-08-08 17:22:00-04:00,RIGL,neutral
1088915.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,RIGL,positive
1088916.0,"Rigel Initiates Phase 1 Clinical Trial Of R835, An IRAK1/4 Inhibitor For Autoimmune And Inflammatory Diseases",2018-06-26 07:32:00-04:00,RIGL,negative
1088917.0,"Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street",2018-06-21 08:39:00-04:00,RIGL,neutral
1088918.0,Rigel To Present Phase 2 Results For Fostamatinib In Autoimmune Hemolytic Anemia At EHA,2018-06-12 07:31:00-04:00,RIGL,neutral
1088919.0,44 Biggest Movers From Yesterday,2018-06-12 04:49:00-04:00,RIGL,neutral
1088920.0,32 Stocks Moving In Monday's Mid-Day Session,2018-06-11 12:25:00-04:00,RIGL,neutral
1088921.0,41 Biggest Movers From Yesterday,2018-05-31 04:45:00-04:00,RIGL,neutral
1088922.0,"Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA",2018-05-30 08:14:00-04:00,RIGL,positive
1088923.0,Rigel Names Dean Schorno CFO,2018-05-30 07:32:00-04:00,RIGL,neutral
1088924.0,Rigel Announces Availability of TAVALISSE,2018-05-29 07:42:00-04:00,RIGL,neutral
1088925.0,"Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings",2018-05-02 07:41:00-04:00,RIGL,neutral
1088926.0,Rigel Pharmaceuticals Q1 EPS $(0.17) Inline,2018-05-01 16:28:00-04:00,RIGL,neutral
1088927.0,"Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings",2018-05-01 07:51:00-04:00,RIGL,neutral
1088928.0,Rigel Pharmaceuticals Reports TAVALISSE Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo,2018-04-30 07:33:00-04:00,RIGL,neutral
1088929.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap",2018-04-29 08:11:00-04:00,RIGL,neutral
1088930.0,Rigel Prices 16M Share Public Offering Of Common Stock @$3.90/Share,2018-04-20 03:59:00-04:00,RIGL,positive
1088931.0,"Benzinga Pro's Most-Searched Tickers For Morning Of Thurs., Apr. 19, 2018",2018-04-19 07:12:00-04:00,RIGL,neutral
1088932.0,Rigel Pharma Reports 15M Share Common Stock Offering,2018-04-18 16:34:00-04:00,RIGL,positive
1088933.0,Analysts See 100% Upside To Rigel After Tavalisse Approval,2018-04-18 13:23:00-04:00,RIGL,positive
1088934.0,"Benzinga Pro's Most-Searched Tickers For Wed., Apr. 18, 2018",2018-04-18 11:58:00-04:00,RIGL,neutral
1088935.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-18 08:54:00-04:00,RIGL,neutral
1088936.0,24 Stocks Moving In Wednesday's Pre-Market Session,2018-04-18 08:02:00-04:00,RIGL,neutral
1088937.0,Rigel Pharma Shares Spiking Premarket on Heavy Volume Following FDA Approval of Tavalisse Announced Tuesday,2018-04-18 06:41:00-04:00,RIGL,positive
1088938.0,Rigel Pharmaceuticals Shares Up 5.6% After Hours Following Announcement Of FDA Approval For TAVALISSE,2018-04-17 17:38:00-04:00,RIGL,positive
1088939.0,"Rigel Pharma Shares Resume Trade, Spike ~8% Higher",2018-04-17 17:20:00-04:00,RIGL,positive
1088940.0,"Rigel Pharma Press Release Confirms FDA Approval of TAVALISSE, Shares Remain Halted",2018-04-17 16:52:00-04:00,RIGL,positive
1088941.0,"UPDATE: FDA Access Data .gov Site Shows FDA Approved 100, 150mg Tavalisse By Riconpharma LLC",2018-04-17 13:48:00-04:00,RIGL,positive
1088942.0,Rigel Pharma Shares Halted With Code News Pending,2018-04-17 13:45:00-04:00,RIGL,positive
1088943.0,"Traders Attributing Move Higher In Rigel Pharma, Circuit Breaker To Report Of FDA Approval For TAVALISSE",2018-04-17 13:41:00-04:00,RIGL,positive
1088944.0,"Rigel Pharmaceuticals Halted On Circuit Breaker, Up 10.19% At $4.11/Share",2018-04-17 13:31:00-04:00,RIGL,neutral
1088945.0,REMINDER: FDA PDUFA Dates Today Include: Ultragenyx BLA  for Burosumab and Rigel Pharma for Fostamatinib,2018-04-17 07:13:00-04:00,RIGL,neutral
1088946.0,"The Week Ahead: Netflix Earnings, Big Bank Results, FDA Actions Abound",2018-04-16 12:10:00-04:00,RIGL,neutral
1088947.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-13 11:38:00-04:00,RIGL,neutral
1088948.0,41 Biggest Movers From Yesterday,2018-04-13 05:04:00-04:00,RIGL,neutral
1088949.0,"UPDATE: Rigel Says FDA Continues To Review NDA, PDUFA Action Date Of Apr. 17, '18",2018-04-12 16:00:00-04:00,RIGL,neutral
1088950.0,UPDATE: Rigel Says Website Has Been Corrected,2018-04-12 15:59:00-04:00,RIGL,neutral
1088951.0,"UPDATE: Rigel Cites Error By External Host Of IR Website, Inaccurate Info Was Displayed Related To FDA Review Of NDA For Fostamatib",2018-04-12 15:59:00-04:00,RIGL,negative
1088952.0,"'...$RIGL...spox blames Nasdaq. ""NASDAQ inadvertently issued a release today. You can contact them for more details on that. Rigel continues to anticipate FDA action on TAVALISSE on or around April 17.""'",2018-04-12 15:42:00-04:00,RIGL,negative
1088953.0,Shares of Rigel Pharmaceuticals Fell Sharply Following Co. Removing FDA Approval Language With Regard To TAVALISSE From Co. Site,2018-04-12 14:33:00-04:00,RIGL,positive
1088954.0,"Rigel Pharmaceuticals Shares Up 14.3%, Traders Circulating Co. Website Post That TAVALISSE Is The Co.'s First FDA Approved Product",2018-04-12 14:09:00-04:00,RIGL,positive
1088955.0,Rigel Pharma Option Alert: Apr 20 $2.5 Puts Sweep (24) at the Bid: 2344 @ $0.35 vs 23342 OI; Earnings 5/1 After Close [est] Ref=$3.71,2018-04-12 13:08:00-04:00,RIGL,positive
1088956.0,35 Biggest Movers From Yesterday,2018-04-04 04:20:00-04:00,RIGL,neutral
1088957.0,Mid-Afternoon Market Update: Quest Resource Falls Following Q4 Results; Bio-Path Shares Surge,2018-04-03 14:33:00-04:00,RIGL,positive
1088958.0,26 Stocks Moving In Tuesday's Mid-Day Session,2018-04-03 12:29:00-04:00,RIGL,neutral
1088959.0,"Rigel Pharma Price Target Lowered From $7 To $6 By Cantor Fitzgerald, Overweight Rating Reiterated",2018-04-03 10:11:00-04:00,RIGL,negative
1088960.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2018-04-03 08:14:00-04:00,RIGL,neutral
1088961.0,17 Stocks Moving In Tuesday's Pre-Market Session,2018-04-03 08:02:00-04:00,RIGL,neutral
1088962.0,Rigel Did Not Achieve Primary Endpoint For Phase 2 Study Of Fostamatinib In IgA Nephropathy,2018-04-03 07:05:00-04:00,RIGL,neutral
1088963.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences",2018-03-30 09:46:00-04:00,RIGL,neutral
1088964.0,Rigel Pharma Option Alert: Apr 20 $5 Calls at the Ask: 5000 @ $0.7 vs 5611 OI; Earnings 5/1 After Close [est] Ref=$3.625,2018-03-28 12:29:00-04:00,RIGL,positive
1088965.0,41 Biggest Movers From Yesterday,2018-03-08 04:46:00-05:00,RIGL,neutral
1088966.0,"Rigel Pharma Reports Q4 EPS $(0.18) vs $(0.13) Est., Sales $0",2018-03-06 16:19:00-05:00,RIGL,neutral
1088967.0,Rigel Pharmaceuticals Q4 Earnings Outlook,2018-03-06 08:38:00-05:00,RIGL,neutral
1088968.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-02 14:12:00-05:00,RIGL,neutral
1088969.0,"Rigel Pharma Shares Make Parabolic Move, Now Lower; Traders Circulate FDA.gov Access Data Alert Showing Orphan Drug Designation For Fostamatinib",2018-02-01 12:05:00-05:00,RIGL,positive
1088970.0,"Benzinga's Top Upgrades, Downgrades For December 15, 2017",2017-12-15 08:57:00-05:00,RIGL,positive
1088971.0,"Cantor Fitzgerald Initiates Coverage On Rigel Pharmaceuticals with Overweight Rating, Announces $6.00 Price Target",2017-12-15 08:34:00-05:00,RIGL,negative
1088972.0,"Rigel Pharma Reports CFO Ryan Maynard To Resign; VP, Finance Nelson Cabatuan Will Serve As Co.'s Interim Principal Accounting Officer",2017-12-15 07:31:00-05:00,RIGL,negative
1088973.0,"Rigel Pharmaceuticals Reports Q3 EPS $(0.14) vs $(0.15) Est., Sales $900K vs $3.76M In Same Qtr. Last Year",2017-11-07 16:47:00-05:00,RIGL,neutral
1088974.0,"Benzinga's Top Upgrades, Downgrades For November 6, 2017",2017-11-06 09:53:00-05:00,RIGL,positive
1088975.0,"H.C. Wainwright Assumes Rigel Pharmaceuticals at Buy, Announces price target $7.00",2017-11-06 07:20:00-05:00,RIGL,neutral
1088976.0,"Rigel Pharma To Report Q3 Earnings On Tues., Nov. 7 After Market Close",2017-10-31 07:40:00-04:00,RIGL,neutral
1088977.0,Rigel Prices 18.1M Share Common Stock Offering @$3.35/Share,2017-10-05 03:56:00-04:00,RIGL,positive
1088978.0,"Rigel Pharma Shares Recently Turn Positive, Now Up 9% For Session; Stock Up 53% Over Last 5 Trading Sessions",2017-10-04 11:40:00-04:00,RIGL,positive
1088979.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-10-04 08:07:00-04:00,RIGL,neutral
1088980.0,A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Economic Reports,2017-10-04 07:20:00-04:00,RIGL,negative
1088981.0,"6 Stocks To Watch For October 4, 2017",2017-10-04 05:01:00-04:00,RIGL,neutral
1088982.0,Rigel Pharma Reports Offering Of $40M in Common Shares,2017-10-03 16:01:00-04:00,RIGL,positive
1088983.0,Mid-Day Market Update: Dow Rises 70 Points; RedHill Biopharma Shares Slide,2017-10-03 12:00:00-04:00,RIGL,positive
1088984.0,"Rigel Pharma Shares Up 14% In Tuesday's Premarket, Continuing Run From Mon.; Shares Rallied 32+% On Mon. Following News The FDA Indicated It Will Not Hold An AdCom Meeting For Fostamatinib",2017-10-03 07:46:00-04:00,RIGL,positive
1088985.0,Rigel Pharmaceuticals Says They Completed Enrollment Of Stage 1 Of Its Phase 2 Study Of fostamatinib,2017-10-03 07:31:00-04:00,RIGL,neutral
1088986.0,Mid-Afternoon Market Update: Dow Gains 130 Points; CyberOptics Shares Plunge,2017-10-02 14:30:00-04:00,RIGL,positive
1088987.0,Rigel Pharma Shares Up 29.7% Following News FDA Has Indicated It Will Not Hold An Oncology Drugs AdCom Meeting For Fostamatinib,2017-10-02 13:10:00-04:00,RIGL,positive
1088988.0,20 Biggest Mid-Day Gainers For Monday,2017-10-02 12:04:00-04:00,RIGL,neutral
1088989.0,Mid-Day Market Update: Crude Oil Down Over 2%; Endocyte Shares Spike Higher,2017-10-02 12:00:00-04:00,RIGL,negative
1088990.0,Mid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Posts Wider-Than-Expected Loss,2017-10-02 10:12:00-04:00,RIGL,negative
1088991.0,30 Stocks Moving In Monday's Pre-Market Session,2017-10-02 08:11:00-04:00,RIGL,neutral
1088992.0,"UPDATE: Rigel Says FDA Indicated It Expects Meeting The PDUFA Action Date Of Apr. 17, 2018",2017-10-02 07:31:00-04:00,RIGL,neutral
1088993.0,Rigel Pharma Offers Update On FDA Review Of Fostamatinib For ITP: FDA Has Indicated It Will Not Hold Oncology Drugs AdCom Meeting To Discuss NDA,2017-10-02 07:31:00-04:00,RIGL,neutral
1088994.0,"Seeing Notable Block Trade In Rigel Pharmaceuticals, 1.1M Shares At $2.30/Share",2017-09-28 12:32:00-04:00,RIGL,negative
1088995.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-08-31 08:09:00-04:00,RIGL,neutral
1088996.0,Rigel Pharma Spikes to High of $2.43 on Volume,2017-08-14 14:21:00-04:00,RIGL,neutral
1088997.0,Rigel Reports Q2 EPS $(0.16) vs $(0.15) Est.,2017-08-01 16:21:00-04:00,RIGL,neutral
1088999.0,15 Biggest Mid-Day Gainers For Monday,2017-06-19 12:24:00-04:00,RIGL,neutral
1089000.0,15 Stocks Moving In Monday's Pre-Market Session,2017-06-19 08:37:00-04:00,RIGL,neutral
1089001.0,Rigel Pharma's New Drug Application for TAVALISSE is Accepted by the FDA,2017-06-19 07:31:00-04:00,RIGL,positive
1089002.0,"Rigel Reports Q1 EPS $(0.13) vs $(0.12) Est., Sales $3.584M vs $3.33M Est.",2017-05-02 16:58:00-04:00,RIGL,neutral
1089003.0,Rigel Submits NDA to FDA For Fostamatinib,2017-04-17 16:06:00-04:00,RIGL,neutral
1089004.0,Mid-Morning Market Update: Markets Edge Higher; Staples Earnings Miss Views,2017-03-09 09:58:00-05:00,RIGL,negative
1089005.0,Mid-Afternoon Market Update: Dow Falls 50 Points; H & R Block Shares Spike Higher,2017-03-08 14:34:00-05:00,RIGL,negative
1089006.0,Mid-Day Market Update: Crude Oil Down Over 3%; Express Shares Drop On Weak Forecast,2017-03-08 12:50:00-05:00,RIGL,negative
1089007.0,"Rigel Pharma Reports Q4 EPS $(0.16) vs $(0.17) Est., Contract Sales from Collaborations $3M vs $4.25M Est.",2017-03-07 16:02:00-05:00,RIGL,neutral
1089008.0,"Great Point Partners Llc Reports 7.47% Passive Stake in Rigel Pharmaceuticals as of January 31, 2017 in 13G",2017-02-10 12:57:00-05:00,RIGL,positive
1089009.0,Rigel Pharma Prices Offering of 20M Shares at $2/Share,2017-01-31 07:33:00-05:00,RIGL,positive
1089010.0,"Rigel Reports Proposed Public Offering Of Common Stock, Size Not Disclosed",2017-01-30 16:03:00-05:00,RIGL,neutral
1089011.0,"Rigel Announces Offering Of Common Stock, No Size Disclosed",2017-01-30 16:02:00-05:00,RIGL,negative
1089012.0,Rigel Pharma Reports Updates from Clinical Program of Fostamatinib in Patients with Chronic ITP,2017-01-30 07:36:00-05:00,RIGL,neutral
1089013.0,Why The Last Week Of 2016 Could Be Big For Biotech Catalysts,2016-12-27 09:02:00-05:00,RIGL,neutral
1089014.0,10 Stocks With Lowest Close In Three Weeks,2016-12-05 06:18:00-05:00,RIGL,negative
1089015.0,"Rigel Announces Q3 Loss/Share $0.24 vs Est Loss/Share $0.23, Revenue $3.76M vs $3.97M Est",2016-11-01 16:32:00-04:00,RIGL,neutral
1089016.0,Rigel Says It Expects To Submit NDA On FIT Fostamatinib Treatment In Q1 2017,2016-11-01 16:31:00-04:00,RIGL,positive
1089017.0,Mid-Afternoon Market Update: Crude Oil Down Over 2.5%; American Express Shares Gain On Earnings Beat,2016-10-20 15:08:00-04:00,RIGL,positive
1089018.0,18 Biggest Mid-Day Losers For Thursday,2016-10-20 13:07:00-04:00,RIGL,negative
1089019.0,Mid-Day Market Update: Insteel Industries Drops Following Q4 Results; DragonWave Shares Spike Higher,2016-10-20 12:15:00-04:00,RIGL,positive
1089020.0,Rigel Pharma Shares Suffering After Phase 3 Study Failure,2016-10-20 11:40:00-04:00,RIGL,negative
1089021.0,Mid-Morning Market Update: Markets Mostly Higher; Verizon Posts Mixed Q3 Results,2016-10-20 10:05:00-04:00,RIGL,neutral
1089022.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-10-20 08:24:00-04:00,RIGL,neutral
1089023.0,Rigel Pharma Shares to Resume Trade at 7:30 a.m. EDT,2016-10-20 07:11:00-04:00,RIGL,positive
1089024.0,"Rigel Reports Results from Second FIT Phase 3 Study, Long-Term Open-Label Extension Study for Fostamatinib in ITP: Difference Between Treatment, Placebo Did Not Reach Statistical Significance, Did Not Meet Primary Endpoint",2016-10-20 07:10:00-04:00,RIGL,positive
1089025.0,"Rigel Pharma Halted, News Pending",2016-10-20 06:56:00-04:00,RIGL,neutral
1089026.0,18 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-18 06:59:00-04:00,RIGL,neutral
1089027.0,Stocks Hitting 52-Week Highs,2016-10-04 10:22:00-04:00,RIGL,neutral
1089028.0,Watch These 5 Huge Call Purchases In Thursday Trade,2016-09-29 02:30:00-04:00,RIGL,positive
1089029.0,Option Alert: RIGL Dec16 2.5 Calls: 3250 @  ASK  $1.55: 3260 traded vs 415 OI:  Earnings 11/1  $3.59 Ref,2016-09-28 13:59:00-04:00,RIGL,positive
1089030.0,Option Alert: RIGL Dec16 7.5 Calls Sweep: 500 @  ASK  $0.25: 500 traded vs 20 OI:  Earnings 11/1  $3.45 Ref,2016-09-28 09:53:00-04:00,RIGL,positive
1089031.0,UPDATE: Rigel Names Eldon Mayer Chief Commercial Officer,2016-09-15 07:31:00-04:00,RIGL,neutral
1089032.0,"Rigel Restructures to Focus on Fostamatinib Commercialization, To Reduce Workforce By 38% By Eliminating 46 Positions in Research Area; Will Incur $5.7M Cash-Related Expense",2016-09-15 07:31:00-04:00,RIGL,neutral
1089033.0,7 Biggest Price Target Changes For Thursday,2016-09-01 09:38:00-04:00,RIGL,neutral
1089034.0,BMO Thinks Rigel's Fostamatinib Market Opportunity Will Be Further Validated,2016-09-01 08:37:00-04:00,RIGL,positive
1089035.0,12 Biggest Mid-Day Losers For Wednesday,2016-08-31 12:57:00-04:00,RIGL,negative
1089036.0,12 Stocks Moving In Wednesday's Pre-Market Session,2016-08-31 08:22:00-04:00,RIGL,neutral
1089037.0,Mid-Afternoon Market Update: Crude Oil Down 1.3%; Ritchie Bros. Shares Spike Higher,2016-08-30 14:34:00-04:00,RIGL,negative
1089038.0,18 Biggest Mid-Day Gainers For Tuesday,2016-08-30 12:51:00-04:00,RIGL,neutral
1089039.0,Mid-Day Market Update: Abercrombie & Fitch Drops On Wider Loss; Rigel Pharmaceuticals Shares Surge,2016-08-30 12:15:00-04:00,RIGL,neutral
1089040.0,"Jefferies Positive On Rigel Pharma, Sees Potential Upside, Maintains Buy & Raises PT From $7.00 to $8.50 Citing Fosta Success",2016-08-30 12:10:00-04:00,RIGL,positive
1089041.0,Mid-Morning Market Update: Markets Mostly Flat; G-III Apparel Misses Q2 Expectations,2016-08-30 10:12:00-04:00,RIGL,negative
1089042.0,15 Stocks Moving In Tuesday's Pre-Market Session,2016-08-30 08:24:00-04:00,RIGL,neutral
1089043.0,Rigel's Oral Spleen Tyrosine Kinase Inhibitor Meets Primary Endpoint In Final Stage Trial In Chronic ITP,2016-08-30 07:37:00-04:00,RIGL,negative
1089044.0,"BZ NOTE: Rigel Shares Volatile Pre-Market, Traders Skeptical Of Safety Data; 18% Stable Platelet Response vs. Placebo",2016-08-30 07:28:00-04:00,RIGL,positive
1089045.0,Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP,2016-08-30 07:03:00-04:00,RIGL,neutral
1089046.0,"BMO Analysts Initiate Coverage On Rigel Pharma, Seeing 65% Upside",2016-08-01 13:47:00-04:00,RIGL,neutral
1089047.0,Benzinga's Top Initiations,2016-08-01 09:30:00-04:00,RIGL,positive
1089048.0,BMO Capital Initiates Coverage on Rigel Pharmaceuticals at Outperform,2016-08-01 04:24:00-04:00,RIGL,neutral
1089049.0,"Soaring +11% In Pre-Market, Rigel Receives Buy Initiation Amid Fostamatinib Phase 3 Optimism",2016-07-13 09:24:00-04:00,RIGL,positive
1089050.0,H.C. Wainwright Initiates Coverage on Rigel Pharmaceuticals at Buy,2016-07-13 07:09:00-04:00,RIGL,neutral
1089051.0,Piper Jaffray Initiates Coverage on Rigel Pharmaceuticals at Overweight,2016-06-13 06:42:00-04:00,RIGL,negative
1089052.0,"Rigel Reports Inline Q1 EPS $(0.19), Sales $5M Vs Est $4M",2016-05-03 17:54:00-04:00,RIGL,neutral
1089053.0,Rigel Pharma Gets Bulls From JPMorgan Before New Phase 3 Data: What To Know,2016-04-22 10:52:00-04:00,RIGL,neutral
1089054.0,JP Morgan Upgrades Rigel Pharmaceuticals to Overweight,2016-04-22 04:28:00-04:00,RIGL,neutral
1089055.0,Rigel Announces Enrollment Completion of Phase 3 Program,2016-04-01 07:31:00-04:00,RIGL,neutral
1089056.0,Option Alert: RIGL Sep16 2.5 Calls Sweep: 500 @  ASK  $0.60: 500 traded vs 1815 OI:  Earnings 5/5  $2.28 Ref,2016-03-16 10:56:00-04:00,RIGL,positive
1089057.0,"Rigel Reports Q4 EPS $(0.14) vs. Est. $(0.14), Rev. $8.5M vs. Est. $8.9M",2016-03-08 16:07:00-05:00,RIGL,neutral
1089058.0,"Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer",2016-03-08 16:03:00-05:00,RIGL,neutral
1089059.0,Option Alert: RIGL Sep16 2.5 Calls Sweep: 500 @  ASK  $0.54: 500 traded vs 241 OI:  Earnings tmrrw  $2.31 Ref,2016-02-29 12:20:00-05:00,RIGL,positive
1089060.0,Rigel Begins Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia,2016-02-25 07:40:00-05:00,RIGL,neutral
1089061.0,Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP,2016-01-28 07:37:00-05:00,RIGL,neutral
1089062.0,"Rigel Reports Q3 EPS $(0.08) vs. Est. $(0.17), Rev. $13M vs. Est. $5M; Est. May Not Compare",2015-11-03 16:14:00-05:00,RIGL,neutral
1089063.0,"Rigel, Aclaris Therapeutics Sign JAk Inhibitors License Agreement",2015-09-09 08:32:00-04:00,RIGL,positive
1089064.0,Rigel Granted Orphan Drug Designation for Fostamatinib in ITP,2015-09-08 07:30:00-04:00,RIGL,positive
1089065.0,"Rigel Reports Q2 EPS $1.57 vs. Est. $(0.22) Does Not Compare, Rev. $1.541M vs. Est. $2.67M May Not Compare",2015-08-04 17:04:00-04:00,RIGL,neutral
1089066.0,Rigel Shares Spike Higher; May be Attributed to Article 'Experimental drug combined with standard chemo may shrink ovarian cancers',2015-07-01 10:36:00-04:00,RIGL,positive
1089067.0,S-3 from Rigel Pharma Shows Registration for $150M Mixed Securities Shelf Offering,2015-05-07 16:49:00-04:00,RIGL,positive
1089068.0,Shares of Rigel Pull Back on Report They are Not Partners with Bristol Myers on Opdivo for Lung Cancer,2015-03-04 13:49:00-05:00,RIGL,negative
1089069.0,Rigel Pharmaceuticals Reports Q4 EPS -$0.25 Vs Est -$0.26,2015-03-03 07:31:00-05:00,RIGL,neutral
1089070.0,"Earnings Scheduled For March 3, 2015",2015-03-03 04:18:00-05:00,RIGL,neutral
1089071.0,Biotech Stocks Moving Higher,2015-02-23 15:35:00-05:00,RIGL,neutral
1089072.0,Morning Market Gainers,2015-02-23 09:44:00-05:00,RIGL,neutral
1089073.0,"Monday's #PreMarket Movers: Spectrum Pharmaceuticals, Cyberark Software Trending Down",2015-02-23 08:57:00-05:00,RIGL,neutral
1089074.0,Benzinga's Top #PreMarket Gainers,2015-02-23 08:09:00-05:00,RIGL,positive
1089075.0,Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications,2015-02-23 08:04:00-05:00,RIGL,negative
1089076.0,Rigel Sees Current Cash Sufficient To Fund Operations through Q4 2016,2015-01-15 12:27:00-05:00,RIGL,neutral
1089077.0,From Webcast: Rigel Sees Results From Phase 3 Trials In 1H 2016; Targets Approval For Fostamatinib End of 2017,2015-01-15 12:20:00-05:00,RIGL,positive
1089078.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4,2015-01-13 11:34:00-05:00,RIGL,neutral
1089079.0,UPDATE: Rigel Sees Ending 2015 With Cash Sufficient For Operations Through Fourth Quarter 2016,2015-01-08 07:47:00-05:00,RIGL,neutral
1089080.0,UPDATE: Rigel Earns $5.75M Payment From AstraZeneca; Sees Ending 2015 With Cash Equivalents of $68M,2015-01-08 07:45:00-05:00,RIGL,neutral
1089081.0,Rigel Pharmaceuticals To Present at J.P. Morgan Healthcare Conference; Provides Company Updates,2015-01-08 07:41:00-05:00,RIGL,neutral
1089082.0,Rigel Pharmaceuticals CEO James Gower To Retire; Raul Rodriguez As Successor,2014-11-24 07:34:00-05:00,RIGL,positive
1089083.0,"Rigel Pharmaceuticals, Inc. Reports Q3 EPS of $(0.24) vs $(0.27) Est",2014-11-04 07:34:00-05:00,RIGL,neutral
1089084.0,What You Need to Know About the Roche-InterMune Deal,2014-08-29 15:51:00-04:00,RIGL,neutral
1089085.0,InterMune's Roche Deal Sends Peer Group Up,2014-08-25 11:38:00-04:00,RIGL,neutral
1089086.0,Morning Market Losers ,2014-08-13 09:51:00-04:00,RIGL,negative
1089087.0,Rigel Pharma Reports R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study,2014-08-13 07:31:00-04:00,RIGL,neutral
1089088.0,Rigel Pharmaceuticals Says There Was No Contract Revenue from Collaborations In Q2 2014; Says Anticipates Reporting Top-Line Results from  Phase 2 R348 Study In Patients With Dry Eye Soon,2014-08-05 07:37:00-04:00,RIGL,negative
1089089.0,Rigel Pharmaceuticals Reports Q2 EPS of $(0.29) vs $(0.25) Est,2014-08-05 07:35:00-04:00,RIGL,neutral
1089090.0,Rigel Initiates Phase 3 Studies Of Fostamatinib In ITP,2014-07-16 08:38:00-04:00,RIGL,neutral
1089091.0,"Corporate Events for the Week of Jun. 2nd, 2014",2014-06-02 18:19:00-04:00,RIGL,neutral
1089092.0,"Rigel Pharmaceuticals, Inc. Reports Q1 EPS of $(0.25), Inline",2014-05-07 07:35:00-04:00,RIGL,neutral
1089093.0,Benzinga's Top #PreMarket Gainers,2014-03-06 08:11:00-05:00,RIGL,positive
1089094.0,"Rigel Pharmaceuticals, Inc. Reports Q4 EPS of $(0.19) vs $(0.25) Est",2014-03-04 07:32:00-05:00,RIGL,neutral
1089095.0,"Earnings Scheduled For March 4, 2014",2014-03-04 04:35:00-05:00,RIGL,neutral
1089096.0,"Stocks to Watch for December 30, 2013",2013-12-30 12:03:00-05:00,RIGL,neutral
1089097.0,"Rigel Pharmaceuticals, Inc. Reports Q3 EPS of $(0.27) vs $(0.29) Est",2013-11-05 07:35:00-05:00,RIGL,neutral
1089098.0,Shares of Rigel Pharma to Resume Trade at 8AM EDT,2013-10-24 07:56:00-04:00,RIGL,positive
1089099.0,PREVIEW: Rigel Pharmaceuticals to Resume Trading at 8:00 AM ET,2013-10-24 07:42:00-04:00,RIGL,neutral
1089100.0,Rigel Pharma Says R333 Did Not Meet Primary Endpoint,2013-10-24 07:34:00-04:00,RIGL,neutral
1089101.0,Shares of Rigel Pharma Halted News Pending,2013-10-24 07:25:00-04:00,RIGL,positive
1089102.0,Benzinga's Top Pre-Market Losers,2013-09-05 08:15:00-04:00,RIGL,negative
1089103.0,"Rigel Pharma Says Will Not Continue Further Development of Fostamatinib for RA, Lymphoma, Cites Insufficient Efficacy Findings, Cutting ~30 Jobs",2013-09-05 07:32:00-04:00,RIGL,negative
1089104.0,Leerink Swann Reiterates Outperform On Rigel Pharma As Shares Plunge 12+% On Missed R343 Trial Endpoints,2013-08-26 12:02:00-04:00,RIGL,neutral
1089105.0,Morning Market Losers ,2013-08-26 10:15:00-04:00,RIGL,negative
1089106.0,Benzinga's Top Pre-Market Losers,2013-08-26 08:17:00-04:00,RIGL,negative
1089107.0,Shares of Rigel Pharma Resume Trade Down 33%,2013-08-26 08:00:00-04:00,RIGL,positive
1089108.0,Shares of Rigel Pharma to Resume Trade at 8AM EDT,2013-08-26 07:42:00-04:00,RIGL,positive
1089109.0,"UPDATE: Rigel Pharma Announces R343 Did Not Meet Primary, Secondary Endpoints in Asthma Trial",2013-08-26 07:32:00-04:00,RIGL,neutral
1089110.0,Shares of Rigel Pharm Halted to Announce R343 Did Not Meet Primary Endpoint,2013-08-26 07:30:00-04:00,RIGL,positive
1089111.0,"Weekly Preview: Earnings Season Nears The End, China in Focus",2013-08-02 15:28:00-04:00,RIGL,neutral
1089112.0,UPDATE: Jefferies Lowers PT on Rigel Pharmaceuticals Following Return of Fostamatinib Rights,2013-06-05 11:42:00-04:00,RIGL,negative
1089113.0,"Jefferies Maintains Buy on Rigel Pharmaceuticals, Inc., Lowers PT to $6.00",2013-06-05 07:27:00-04:00,RIGL,negative
1089114.0,"Market Wrap for Tuesday, June 4: Stocks Retreat as Uncertainty Rises ",2013-06-04 16:16:00-04:00,RIGL,negative
1089115.0,Afternoon Market Losers,2013-06-04 14:44:00-04:00,RIGL,negative
1089116.0,UPDATE: Oppenheimer Downgrades Rigel Pharmaceuticals on Disappointing Ph.III OKSIRA-2/3 Studies ,2013-06-04 13:19:00-04:00,RIGL,negative
1089117.0,UPDATE: J.P. Morgan Downgrades Rigel Pharmaceuticals to Neutral Following AZN Decision,2013-06-04 11:55:00-04:00,RIGL,neutral
1089118.0,Traders Passing Around Fool Article 'AstraZeneca Writes Off $140 Million Following Product Trial' Related to Results from Fostamatinib,2013-06-04 11:27:00-04:00,RIGL,negative
1089119.0,Stocks Hitting 52-Week Lows,2013-06-04 10:46:00-04:00,RIGL,negative
1089120.0,"Oppenheimer Downgrades Rigel Pharmaceuticals, Inc. to Perform, Removes $10.00 PT",2013-06-04 10:35:00-04:00,RIGL,neutral
1089121.0,Morning Market Losers,2013-06-04 10:18:00-04:00,RIGL,negative
1089122.0,"Canaccord Genuity Maintains Hold on Rigel Pharmaceuticals, Inc., Lowers PT to $4.00",2013-06-04 10:01:00-04:00,RIGL,negative
1089123.0,"JP Morgan Downgrades Rigel Pharmaceuticals, Inc. to Neutral",2013-06-04 09:52:00-04:00,RIGL,positive
1089124.0,"Oppenheimer Downgrades Rigel Pharmaceuticals, Inc. to Perform",2013-06-04 08:44:00-04:00,RIGL,neutral
1089125.0,UPDATE: Piper Jaffray Downgrades Rigel Pharmaceuticals on the Return of Fostamatinib,2013-06-04 08:31:00-04:00,RIGL,neutral
1089126.0,Benzinga's Top Pre-Market Losers,2013-06-04 08:18:00-04:00,RIGL,negative
1089127.0,Benzinga's Top Downgrades,2013-06-04 07:29:00-04:00,RIGL,positive
1089128.0,"Piper Jaffray Downgrades Rigel Pharmaceuticals, Inc. to Neutral, Lowers PT to $6.00",2013-06-04 06:57:00-04:00,RIGL,negative
1089129.0,"Rigel, AstraZeneca Announce Topline Results from OSKIRA-2 and OSKIRA-3 Phase 3 Clinical Trials Investigating Fostamatinib",2013-06-04 06:02:00-04:00,RIGL,neutral
1089130.0,"Rigel Pharmaceuticals, Inc. Reports Q1 EPS of $(0.29) vs $(0.30) Est",2013-05-07 07:34:00-04:00,RIGL,neutral
1089131.0,9 Technical Setups for the Week Ahead,2013-04-22 15:08:00-04:00,RIGL,neutral
1089132.0,"Stocks to Watch for April 19, 2013",2013-04-19 08:48:00-04:00,RIGL,neutral
1089133.0,"Stocks to Watch for April 18, 2013",2013-04-18 08:36:00-04:00,RIGL,neutral
1089134.0,"Stocks to Watch for April 11, 2013",2013-04-11 08:54:00-04:00,RIGL,neutral
1089135.0,Morning Market Losers,2013-04-05 10:48:00-04:00,RIGL,negative
1089136.0,UPDATE: BMO Capital Markets Downgrades Rigel Pharmaceuticals to Market Perform on Mixed OSKIRA-1 Results,2013-04-05 10:35:00-04:00,RIGL,neutral
1089137.0,"Mid-Morning Market Update: Markets Tumble, F5 Networks Cuts View",2013-04-05 10:12:00-04:00,RIGL,negative
1089138.0,"BMO Capital Downgrades Rigel Pharmaceuticals, Inc. to Market Perform, Lowers PT to $8.00",2013-04-05 07:41:00-04:00,RIGL,negative
1089139.0,AstraZeneca Announces Results from OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis ,2013-04-05 05:58:00-04:00,RIGL,neutral
1089140.0,"Citigroup Maintains Neutral on Rigel Pharmaceuticals, Inc., Raises PT to $7.00",2013-03-06 07:59:00-05:00,RIGL,neutral
1089141.0,UPDATE: JP Morgan Maintains Rigel Pharmaceuticals at Overweight Post 4Q Results,2013-03-05 13:08:00-05:00,RIGL,negative
1089142.0,UPDATE: Piper Jaffray Raises PT to $9 on Rigel Pharmaceuticals Ahead of Fostamatinib Readout,2013-03-05 12:58:00-05:00,RIGL,neutral
1089143.0,"Piper Jaffray Maintains Overweight on Rigel Pharmaceuticals, Inc., Raises PT to $9.00",2013-03-05 08:54:00-05:00,RIGL,negative
1089144.0,"Rigel Pharmaceuticals, Inc. Reports Q4 EPS of $(0.30) vs $(0.32) Est",2013-03-05 07:30:00-05:00,RIGL,neutral
1089145.0,"Earnings Scheduled For March 5, 2013",2013-03-05 04:12:00-05:00,RIGL,neutral
1089146.0,"Option Alert: Rigel Pharmaceuticals June 10/15 Call Spread; 1,441 Contracts Traded at $0.85, Currently $6.74",2013-02-19 10:29:00-05:00,RIGL,positive
1089147.0,UPDATE: Stifel Nicolaus Cuts PT to Rigel Pharmaceuticals on Model Changes Post Data  ,2012-12-14 12:42:00-05:00,RIGL,negative
1089148.0,"Stifel Nicolaus Maintains Buy on Rigel Pharmaceuticals, Inc., Lowers PT to $11.00",2012-12-14 08:08:00-05:00,RIGL,negative
1089149.0,"Mid-Afternoon Market Update: SolarCity Hangs on to Gains, Rigel Pharma Continues to Hurt",2012-12-13 15:35:00-05:00,RIGL,negative
1089150.0,"JP Morgan Maintains Overweight on Rigel Pharmaceuticals, Inc., Lowers PT to $10.00",2012-12-13 15:02:00-05:00,RIGL,negative
1089151.0,UPDATE: Jefferies Cuts PT to $15 on Rigel Pharmaceuticals on Disappointing Fostamatinib Results  ,2012-12-13 14:11:00-05:00,RIGL,negative
1089152.0,"Mid-Day Market Update: Markets Go Red, SolarCity IPO a Success",2012-12-13 13:54:00-05:00,RIGL,positive
1089153.0,UPDATE: Piper Jaffray Cuts PT to $8 on Rigel Pharmaceuticals Following Disappointing Phase II Results  ,2012-12-13 13:36:00-05:00,RIGL,negative
1089154.0,Rigel Pharma Shares Sink as Fostamatinib Fails to Hit Secondary Endpoint,2012-12-13 12:12:00-05:00,RIGL,negative
1089155.0,"Citigroup Downgrades Rigel Pharmaceuticals, Inc. to Neutral, Lowers PT to $6.00",2012-12-13 11:15:00-05:00,RIGL,negative
1089156.0,"Mid-Morning Market Update: Markets Cautiously Rising, Best Buy Boosts ",2012-12-13 10:59:00-05:00,RIGL,positive
1089157.0,"Jefferies Maintains Buy on Rigel Pharmaceuticals, Inc., Lowers PT to $15.00",2012-12-13 10:58:00-05:00,RIGL,negative
1089158.0,"Piper Jaffray Maintains Overweight on Rigel Pharmaceuticals, Inc., Lowers PT to $8.00",2012-12-13 10:37:00-05:00,RIGL,negative
1089159.0,Stocks Hitting 52-Week Lows,2012-12-13 10:17:00-05:00,RIGL,negative
1089160.0,Morning Market Losers,2012-12-13 10:02:00-05:00,RIGL,negative
1089161.0,Benzinga's Top Pre-Market Losers,2012-12-13 08:16:00-05:00,RIGL,negative
1089162.0,"UBS Initiates Coverage on Rigel Pharmaceuticals, Inc. at Neutral, Announces $9.00 PT",2012-11-29 12:05:00-05:00,RIGL,neutral
1089163.0,"UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Rigel Pharmaceuticals",2012-11-07 10:19:00-05:00,RIGL,neutral
1089164.0,"Jefferies & Company Maintains Rigel Pharmaceuticals at Buy, Raises PT from $14 to $21",2012-11-07 07:08:00-05:00,RIGL,neutral
1089165.0,From Earlier: Rigel Pharmaceuticals Reports Q3 EPS $-0.36 vs $-0.32 Est,2012-11-06 11:13:00-05:00,RIGL,neutral
1089166.0,"UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on Rigel Pharmaceuticals",2012-10-15 11:56:00-04:00,RIGL,negative
1089167.0,"Piper Jaffray Maintains Rigel Pharmaceuticals at Overweight, Lowers PT from $16 to $14",2012-10-15 09:36:00-04:00,RIGL,negative
1089168.0,Benzinga Mid-Day Market Update,2012-10-03 14:38:00-04:00,RIGL,neutral
1089169.0,Rigel Announces Pricing Of 13.685M Share Public Offering at $9.50 per Share,2012-10-03 09:29:00-04:00,RIGL,positive
1089170.0,Benzinga's Top Pre-Market Losers,2012-10-03 08:32:00-04:00,RIGL,negative
1089171.0,Rigel Announces Proposed Public Offering Of Common Stock,2012-10-02 16:11:00-04:00,RIGL,neutral
1089172.0,"JP Morgan Maintains Rigel Pharmaceuticals at Overweight, Raises PT from $14 to $15",2012-08-07 14:55:00-04:00,RIGL,neutral
1089173.0,Rigel Pharmaceuticals Reports Q2 EPS $-0.35 vs $-0.35 Est,2012-08-07 07:40:00-04:00,RIGL,neutral
1089174.0,"Dendreon, Pharmacyclics and Other Biotech Takeover Targets",2012-07-10 14:07:00-04:00,RIGL,neutral
1089175.0,"Option Alert: Rigel Pharmaceuticals December 10 Call; Block Trade: 2,159 Contracts; Currently $8.81",2012-06-21 10:46:00-04:00,RIGL,negative
1089176.0,AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma  ,2012-06-19 08:04:00-04:00,RIGL,positive
1089177.0,"Option Alert: Rigel Pharmaceuticals May 7.5 Put; Block Trade: 2,500 Contracts",2012-05-10 11:41:00-04:00,RIGL,negative
1089178.0,Rigel Pharmaceuticals Reports Q1 EPS $-0.32 vs $-0.31 Est,2012-05-01 16:32:00-04:00,RIGL,neutral
1089179.0,"Option Alert: Rigel Pharmaceuticals December 10 Call; Block Trade: 2,500 Contracts",2012-04-24 10:10:00-04:00,RIGL,negative
1089180.0,"Canaccord Initiates Coverage on Rigel Pharmaceuticals at Hold, Announces PT of $8",2012-03-26 09:01:00-04:00,RIGL,neutral
1089181.0,Piper Jaffray Reiterates Overweight on Rigel Pharmaceuticals ahead of Phase III Data,2012-03-06 09:04:00-05:00,RIGL,negative
1089182.0,Benzinga's Top Upgrades,2012-02-22 08:47:00-05:00,RIGL,positive
1089183.0,"Financial Breakfast: Morning News Summary for February 22, 2012",2012-02-22 07:33:00-05:00,RIGL,neutral
1089184.0,"Citigroup Upgrades Rigel Pharmaceuticals from Neutral to Buy, Maintains PT at $13",2012-02-22 06:28:00-05:00,RIGL,neutral
1089185.0,Rigel Announces Initiation of Clinical Trials in Two Immunology Programs  ,2012-01-05 07:33:00-05:00,RIGL,neutral
1089186.0,Rigel Announces Initiation of Clinical Trials in Two Immunology Programs  ,2012-01-05 07:32:00-05:00,RIGL,neutral
1089187.0,"Piper Jaffray Maintains OW, PT on Rigel Pharmaceuticals After Consistent Long Term Safety Data",2011-11-10 07:56:00-05:00,RIGL,positive
1089188.0,J.P. Morgan Initiates Coverage on Rigel Pharmaceuticals,2011-09-29 07:42:00-04:00,RIGL,neutral
1089189.0,"JP Morgan Initiates Rigel Pharmaceuticals at Overweight, $14 PT",2011-09-29 06:18:00-04:00,RIGL,neutral
1089190.0,Rigel Pharmaceuticals Reports Q2 EPS $(0.37) vs $(0.38) Est; Revenues $395K vs $420.00K Est		,2011-08-02 07:41:00-04:00,RIGL,neutral
1089191.0,Calls Purchased on Rigel Pharmaceuticals,2011-05-26 11:31:00-04:00,RIGL,neutral
1089192.0,Rigel Announces Prices Public Offering of 16.3M Shares at $8.00 per Share ,2011-05-26 09:02:00-04:00,RIGL,positive
1089193.0,Benzinga's Top Pre-Market NASDAQ Losers,2011-05-26 08:23:00-04:00,RIGL,negative
1089194.0,Rigel Announces Proposed Public Offering of Common Stock,2011-05-25 16:02:00-04:00,RIGL,neutral
1089195.0,Rigel Assumes Development Responsibility for Inhaled Asthma Therapy (RIGL),2011-05-06 07:31:00-04:00,RIGL,neutral
1089196.0,Jefferies Believes In A Long-Term Upside for RIGL,2011-05-04 08:31:00-04:00,RIGL,neutral
1089197.0,Citigroup Updates Rigel Pharmeceuticals After Healthcare Conferences (RIGL),2011-03-03 08:27:00-05:00,RIGL,neutral
1089198.0,Rigel Pharmaceuticals Reports Uneventful 4Q,2011-03-01 08:59:00-05:00,RIGL,negative
1089199.0,Wells Fargo Initiating Coverage On RIGL With An Outperform Rating And A $10-12 Valuation Range,2010-12-10 10:41:00-05:00,RIGL,positive
1089200.0,"Benzinga's After Hours Decliners (EOG, RGL, BKE)",2010-06-02 18:35:00-04:00,RIGL,neutral
1089201.0,RIGL Highlights Clinical and Preclinical Pipeline,2010-03-26 14:07:00-04:00,RIGL,neutral
1089202.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,RIGL,positive
1089203.0,"Benzinga’s Top Pre-Market Losers (RIGL, FSLR, GILD, STP, GSK)",2010-02-22 08:52:00-05:00,RIGL,negative
1089204.0,"Movement Expected In The Shares Of These Companies Amid Significant Events (BRK.B, BX, JPM, ORCL,YHOO) ",2010-02-16 16:32:00-05:00,RIGL,positive
1089205.0,"Rigel Pharmaceuticals, Inc. (RIGL) Maintains An 1-Overweight Rating",2010-02-16 13:22:00-05:00,RIGL,neutral
1089206.0,"Pharmaceutical Giants AstraZeneca (AZN), Rigel (RIGL) Collaborate On Arthritis Drug ",2010-02-16 09:48:00-05:00,RIGL,neutral
1089207.0,"Company News for February 16, 2010 - Corporate Summary",2010-02-16 09:38:00-05:00,RIGL,neutral
1089208.0,"Benzinga’s Top Pre-Market Gainers (NIHD, RIGL, APWR, RTIX, ARTG)",2010-02-16 08:37:00-05:00,RIGL,positive
